The Committee of Human Medicinal Products in Europe is recommending that daratumumab (also known as Darzalex®) has its licence extended to include combination treatments for myeloma patients.
It's already licensed in Europe for use on its own. The recommendation has now been passed to the European Commission which has 60 days to issue final guidance on whether the licence should be extended. It is very rare for the Commission to go against a CHMP recommendation.
You can find out more here: t.co/1ZzLkMMVHc
